GT Biopharma Inc (NAS:GTBP)

$ 3 0.06 (2.04%) Market Cap: 6.70 Mil Enterprise Value: -3.21 Mil PE Ratio: 0 PB Ratio: 3.19 GF Score: 34/100

GT Biopharma Inc Annual Shareholders Meeting Transcript
Jun 28, 2023
GT Biopharma Inc at HC Wainwright Cell Therapy Virtual Conference Transcript
Feb 28, 2023
GT Biopharma Inc at LD Micro Main Event Transcript
Oct 26, 2022
GT Biopharma Inc Extraordinary Shareholders Meeting Transcript
Oct 10, 2022
GT Biopharma Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Sep 13, 2022
GT Biopharma Inc Annual Shareholders Meeting Transcript
Jun 08, 2022
GT Biopharma Inc at B Riley Oncology Conference (Virtual) Transcript
Jan 27, 2022
GT Biopharma Inc to Discuss Management Update Call Transcript
Nov 30, 2021
Q2 2021 GT Biopharma Inc Earnings Call Transcript
Aug 13, 2021

$300.3 (-7.40%)

Earnings
GT Biopharma Inc at Raymond James Human Health Innovation Conference (Virtual) Transcript
Jun 22, 2021

GT Biopharma Inc at H C Wainwright Global Investment Conference (Virtual) Transcript

Sep 13, 2022 / 02:30PM GMT

Release Date Price: $66 (-9.47%)

Transcript

Jason Shieh

H.C. Wainwright & Co. - Analyst

Hello, everyone, and thank you for joining the H.C. Wainwright 24th Annual Global Investment Hybrid Conference. My name is Jason Shieh, and I'm a H.C. Wainwright healthcare research associate. I'd like to welcome our next speaker, Michael Breen, Interim CEO, Executive Chairman, Board of Directors; and Gavin Choy, Chief Clinical Development Officer of GT Biopharma, a clinical stage immuno-oncology company, focused on developing innovative therapeutic based on proprietary natural killer cell engager known as TriKE. And thank you, gentlemen.

Michael Breen

GT Biopharma, Inc. - Executive Chairman & Interim CEO

Thank you, Jason. Good morning, everyone, and thank you for taking the time to join us this morning and listen to our presentation. Much appreciated. And if I can just take you through the first forward-looking statement, which is our standard form disclaimer. I'll not bore you with the minutiae [set out in this], but if you just all please take time to read through that, that would be helpful.

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.